MedPath

Cerebellar Transcranial Direct Current Stimulation (tDCS) in Patients With Isolated Cervical Dystonia (CD)

Not Applicable
Recruiting
Conditions
Isolated Cervical Dystonia
Registration Number
NCT07014384
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Brief Summary

Cervical dystonia (CD) is a movement disorder characterized by involuntary muscle contractions of the neck, leading to abnormal head postures and movement, pain and impaired motor function. Current treatments for CD, such as botulinum toxin injections and physical therapy, may not always provide sufficient relief of symptoms and may fail to offer long-term benefits for patients. As a result, new therapeutic approaches are needed. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that modulates neuronal activity. Recent neurophysiological studies suggest that cerebellar tDCS (ctDCS), in particular, could be beneficial in modulating the activity of the sensorimotor network in CD. This clinical trial aims to investigate the effects of ctDCS on the excitability of the sensorimotor network and motor symptom severity in CD patients. Applying transcranial magnetic stimulation (TMS) we will evaluate the effects of anodal, cathodal and sham ctDCS to improve the understanding of the neurophysiological mechanisms underlying CD and the potential therapeutic role of ctDCS.

Detailed Description

Dystonia is a movement disorder characterized by involuntary, sustained or intermittent muscle contractions, resulting in abnormal movements and postures. CD is the most common form of focal dystonia. It is characterized by abnormal postures or movements of the head. Standard treatment in patients with CD includes regular botulinum toxin injections and physical therapy, but many patients continue to experience symptoms, especially towards the end of the treatment cycle, highlighting the need for alternative treatment options.

One of the challenges in treating CD is the incomplete understanding of its underlying neurophysiological mechanisms. Recently, CD has been recognized as a network disorder, affecting the basal ganglia, the brainstem, the sensorimotor cortex and the cerebellum. So far, there is increasing evidence supporting the role of the cerebellum in the pathophysiology of dystonia, including animal models, neuroimaging and neurophysiological studies, but the exact the role in the proposed dystonia network is only incompletely understood.

TDCS is a form of non-invasive brain stimulation modulating the excitability of superficially located neurons. CtDCS is known to modulate the excitability of neurons of the cerebellar cortex, while the cerebellar nuclei and the brain stem remain unaffected. It has been shown that anodal ctDCS increases and cathodal ctDCS decreases the excitability of the cerebellum.

This randomized and sham-controlled clinical trial aims to investigate the effects of anodal and cathodal ctDCS in CD patients, focusing on both the sensorimotor network excitability and motor symptom severity. Participants will undergo three separated experimental sessions separated by one week, each with a different stimulation condition: anodal, cathodal, and sham ctDCS. Both, the study participants and the experimenter will be blinded to the order of stimulation mode.

The outcome measures will include:

1. Changes in the sensorimotor network before and after ctDCS stimulation, assessed by TMS. Measurements include four main metrics to determine the neurophysiological properties of the sensorimotor network in different ways:

1. Single-pulse TMS (SP-TMS) of the left primary motor cortex, used to quantify the amplitude of motor-evoked potentials (MEPs) in response to unconditioned stimuli,

2. Short-interval intracortical inhibition (SICI),

3. Short-latency afferent inhibition (SAI),

4. Cerebellar brain inhibition (CBI).

2. Clinical motor symptom severity, assessed with the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) before and after each session.

This study aims to improve the understanding of the neurophysiological mechanisms and clinical effects of ctDCS in isolated CD.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Clinical diagnosis of isolated cervical dystonia
  • Written informed consent by the patient
Exclusion Criteria
  • History of other neurological disorders other than CD
  • Secondary dystonia
  • Severe head tremor
  • Intake of centrally acting medication
  • Contraindications to TMS, such as metallic implants, pregnancy and history of seizures

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Changes in sensorimotor networkBaseline (pre-intervention) and immediately after the intervention

Before and after each tDCS intervention, TMS will be used to assess the neurophysiological properties of the sensorimotor network with four main metrics:

1. Single-pulse TMS (SP-TMS):

MEPs will be recorded from the right FDI in response to single-pulse TMS applied over the left primary motor cortex.

2. Short-interval intracortical inhibition (SICI):

SICI will be assessed using a paired-pulse TMS protocol, in which two stimuli are delivered at a short interstimulus interval over the primary motor cortex.

3. Short-latency afferent inhibition (SAI):

SAI consists of electrical conditioning stimuli to the right index finger preceding the test stimulus delivered by TMS to the left primary motor cortex.

4. Cerebellar-brain-inhibition (CBI):

To assess CBI, a conditioning stimulus will be applied over the right cerebellar hemisphere using a second magnetic coil, followed by a cortical test stimulus over the left primary motor cortex.

Secondary Outcome Measures
NameTimeMethod
Clinical symptom severityBaseline (pre-intervention) and immediately after the intervention

Each session will begin and end with a clinical evaluation using the TWSTRS to quantify motor symptom severity, disability and pain associated with CD.

Trial Locations

Locations (1)

Department of Neurology, University Medical Center Hamburg-Eppendorf

🇩🇪

Hamburg, Germany

Department of Neurology, University Medical Center Hamburg-Eppendorf
🇩🇪Hamburg, Germany
Simone Zittel, Dr. med.
Contact
+49 40 7410 53770
s.zittel-dirks@uke.de

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.